Abstract
Cutaneous leishmaniasis is a skin disease that pretends with skin lesions, mainly ulcers, on exposed parts of the body. It’s caused mainly by parasites belonging to the genus Leishmania, such as L. tropica. Medicinal plants, which have sparked recent researches attention, consider one of the richest sources of active compounds against the Leishmania parasite including Peganum harmala. This study was conducted to investigate the antileishmanial effect of different extracts of Peganum harmala grown in Syria, particularly the methanolic extract of seeds and roots as well as its alkaloid fractions on Leishmania tropica promastigotes growth in vitro. After culturing promastigotes and incubating with extracts for 72 h, the surviving promastigotes were counted. The half maximal (50%) inhibitory concentration (IC50) was determined. The experiments were repeated at least three times. The in vitro experiment has demonstrated a concentration-dependent decrease of parasites number caused by the extracts with an IC50 value of 18.61 ± 0.87 µg/mL and 16.41 ± 0.71 µg/mL for the methanolic extract of seeds and roots respectively. While the IC50 of the alkaloid fractions of seeds and roots were 4.97 ± 0.43 μg/mL and 9.23 ± 0.86 μg/mL respectively. There was a significant difference between all extracts and Glucantime which had IC50 = 32.62 ± 0.66 µg/mL.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Asgarpanah J, Ramezanloo F (2012) Chemistry, pharmacology and medicinal properties of Peganum harmala L. Afr J Pharm Pharmacol 6(22):1573–1580. https://doi.org/10.5897/ajpp11.876
Brobst A, Lewis J, Klett B, Haustein C, Shriver J (2009) The free base extraction of harmaline from Penganum harmala. Am J Undergrad Res 8:2–3. https://doi.org/10.33697/ajur.2009.013
Das BB, Ganguly A, Majumder HK (2008) DNA topoisomerases of Leishmania: the potential targets for anti-leishmanial therapy. In: Majumder HK (ed) Drug targets in Kinetoplastid parasites. Springer Science and Business Media, New York, pp 103–115
Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27(5):305–318. https://doi.org/10.1016/j.cimid.2004.03.004
Di Giorgio C, Delmas F, Ollivier E, Elias R, Balansard G, Timon-David P (2004) In vitro activity of the β-carboline alkaloids harmane, harmine, and harmaline toward parasites of the species Leishmania infantum. Exp Parasitol 106(3–4):67–74. https://doi.org/10.1016/j.exppara.2004.04.002
Fadhil S, Reza MH, Rouhollah G, Reza VRM (2007) Spectrophotometric determination of total alkaloids in Peganum harmala L. using bromocresol green. Res J Phytochem 1(2):79–82. https://doi.org/10.3923/rjphyto.2007.79.82
Farouk L, Laroubi A, Aboufatima R, Benharref A, Chait A (2008) Evaluation of the analgesic effect of alkaloid extract of Peganum harmala L.: possible mechanisms involved. J Ethnopharmacol 115(3):449–454. https://doi.org/10.1016/j.jep.2007.10.014
Feily A, Saki J, Maraghi S, Moosavi Z, Khademvatan S, Siahpoosh A (2012) In vitro activity of green tea extract against Leishmania major promastigotes. Int J Clin Pharmacol Ther 50(3):233–236. https://doi.org/10.5414/CP201571
Ghorbani M, Farhoudi R (2018) Leishmaniasis in humans: drug or vaccine therapy? Drug Des Devel Ther 12:25. https://doi.org/10.2147/DDDT.S146521
Hayani K, Dandashli A, Weisshaar E (2015) Cutaneous leishmaniasis in Syria: clinical features, current status and the effects of war. Acta Derm Venereol 95(1):62–66. https://doi.org/10.2340/00015555-1988
Herraiz T, González D, Ancín-Azpilicueta C, Arán VJ, Guillén H (2010) β-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol 48(3):839–845. https://doi.org/10.1016/j.fct.009.12.019
Herraiz T, Guillén H, Arán VJ, Salgado A (2017) Identification, occurrence and activity of quinazoline alkaloids in Peganum harmala. Food Chem Toxicol 103:261–269. https://doi.org/10.1016/j.fct.2017.03.010
Khaliq T, Misra P, Gupta S, Reddy KP, Kant R, Maulik PR, Narender T (2009) Peganine hydrochloride dihydrate an orally active antileishmanial agent. Bioorg Med Chem Lett 19(9):2585–2586. https://doi.org/10.1016/j.bmcl.2009.03.039
Khan FA, Maalik A, Iqbal Z, Malik I (2013) Recent pharmacological developments in β-carboline alkaloid “harmaline”. Eur J Pharmacol 721(1–3):391–394. https://doi.org/10.1016/j.ejphar.2013.05.003
Li S, Cheng X, Wang C (2017) A review on traditional uses, phytochemistry, pharmacology, pharmacokinetics and toxicology of the genus Peganum. J Ethnopharmacol 203:127–162. https://doi.org/10.1016/j.jep.2017.03.049
Maleki F, Zarebavani M, Mohebali M, Dayer MS, Hajialiani F, Tabatabaie F (2017) In vitro and in vivo susceptibility of Leishmania major to some medicinal plants. Asian Pac J Trop Biomed 7(1):37–42. https://doi.org/10.1016/j.apjtb.2016.11.008
Mirzaie M, Nosratabadi SJ, Derakhshanfar A, Sharif I (2007) Antileishmanial activity of Peganum harmala extract on the in vitro growth of Leishmania major promastigotes in comparison to a trivalent antimony drug. Vet Arh 77(4):365
Mishra BB, Kale RR, Singh RK, Tiwari VK (2009) Alkaloids: future prospective to combat leishmaniasis. Fitoterapia 80(2):81–90. https://doi.org/10.1016/j.fitote.2008.10.009
Misra P, Khaliq T, Dixit A, SenGupta S, Samant M, Kumari S, Narender T (2008) Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: an approach for rational drug design. J Antimicrob Chemother 62(5):998–1002. https://doi.org/10.1093/jac/dkn319
Rahimi-Moghaddam P, Ebrahimi SA, Ourmazdi H, Selseleh M, Karjalian M, Haj-Hassani G, Shafiei M (2011) In vitro and in vivo activities of Peganum harmala extract against Leishmania major. J Res Med Sci. 16(8): 1032. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263080/.
Rehman K, Walochnik J, Mischlinger J, Alassil B, Allan R, Ramharter M (2018) Leishmaniasis in northern Syria during civil war. Emerg Infect Dis 24(11):1973. https://doi.org/10.3201/eid2411.172146
Sobhani AM, Ebrahimi SA, Mahmoudian M (2002) An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids. J Pharm Pharm Sci 5(1):19–23
Sundar S, Chakravarty J (2015) An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother 16(2):237–252. https://doi.org/10.1517/14656566.2015.973850
WHO (2019a) Fact sheet, leishmaniasis, https://www.who.int/news-room/factsheets/detail/leishmaniasis. Accessed 30 Jul 2019
WHO (2019b) Neglected tropical diseases. https://www.emro.who.int/neglected-tropical-diseases/countries/cl-syria.html. Accessed 30 Jul 2019
Zhang G, Chi X (2019) The complete chloroplast genome of Peganum harmala. Mitochondrial DNA Part B 4(1):1784–1785. https://doi.org/10.1080/23802359.2019.1612289
Acknowledgement
This study was supported by a Center for Epidemiological and Biological Studies of Leishmaniasis Parasites, Damascus University.
Author information
Authors and Affiliations
Contributions
MM has carried out the laboratory work, perform the Graph pad, Prism analysis, and drafted the first manuscript. SH has supervised the antileishmanial section, KM (My master supervisor) has supervised the extraction section and checked the whole manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Madah, M., Haddad, S. & Khazem, M. Evaluation of the effect of Peganum harmala extracts on the in vitro viability of Leishmania tropica promastigotes in comparison to Glucantime. J Parasit Dis 44, 858–863 (2020). https://doi.org/10.1007/s12639-020-01232-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12639-020-01232-6